Open AccessAtogepant for the Preventive Treatment of Migraine
Author(s) -
Jessica Ailani,
Richard B. Lipton,
Peter J. Goadsby,
Hua Guo,
Rosa Miceli,
Lawrence Severt,
Michelle Finnegan,
Joel M. Trugman
Publication year - 2021
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa2035908
Subject(s) - medicine , migraine , placebo , confidence interval , calcitonin gene related peptide , clinical endpoint , quality of life (healthcare) , randomized controlled trial , anesthesia , receptor , alternative medicine , pathology , neuropeptide , nursing
Atogepant is an oral, small-molecule, calcitonin gene-related peptide receptor antagonist that is being investigated for the preventive treatment of migraine.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom